Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Pleased to share our new paper out today in the British Journal of Haematology.
This is a post-hoc analysis of the BEYOND trial specifically looking at the proportion of NTDT patients that reached and sustained a hemoglobin level of >10 g/dL while on ß, reflecting clinically meaningful impact considering this would now place them in the ‘safe zone’.”
Read the full article in BJHaem.
Article: Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial
Authors: Khaled Musallam X, Ali T. Taher, John B. Porter, Antonis Kattamis, Mrudula B. Glassberg, Luciana Moro Bueno, Patricia Martin-Regueira, Marta Reverte, Loyse Felber Medlin, Matthew Dyer, Kefeng Wang, Maria Domenica Cappellini
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 4, 2026, 21:28New Frontiers in Platelet Biology – BJHaem
-
Aug 4, 2026, 20:48New Real-World Data on Efanesoctocog Alfa From France – CRH French Reference Center for Hemophilia Lyon
-
Aug 4, 2026, 20:37Hisam Siddiqi: Haemoglobinopathy Basics – A Quick Guide to Thalassaemia
-
Aug 4, 2026, 20:36Ifeanyichukwu Ifechidere: AI May Soon Interpret Coagulation Results Better Than Some Healthcare Professionals
-
Aug 4, 2026, 20:35Ediga Naga Pradeep Kumar: Excited to Share My Latest Data Analytics Project – Stroke Risk Analysis Dashboard
-
Aug 4, 2026, 20:34Amar Shah: Improving Thrombolysis for Acute Stroke Through Quality Improvement
-
Aug 4, 2026, 20:33Federica Sepe: Are Biomarkers Finally Ready for Precision Stroke Medicine?
-
Aug 4, 2026, 20:10Kabir Olaniran: Sickle Cell Trait and Chronic Kidney Disease Risk
-
Aug 4, 2026, 19:57Toby Richards: Iron Deficiency Beyond Anaemia in Female Triathletes